SAGE Therapeutics Company
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Headquarters:
Cambridge, Massachusetts, United States
Number Of Exists:
Post-IPO Equity
Total Funding:
1088000000
Founded Date:
01 01 10
Employee Number:
501-1000
Investment Stage:
N/A
Last Funding Type:
Post-IPO Equity
Investor Type:
Company
Investors Number:
6
Last Funding Date:
27 11 20
Technology:
P4 Medicine
Funding Status:
IPO
Estimated Revenue:
$50M to $100M
Industry:
Biotechnology, Health Care, Science and Engineering